Table II Open in new tab Prognostic...

	N	Recurrence-free survival	Invasive recurrence-free survival
Total	94
Fertility sparing surgery			0.003		0.001		0.75
No	15	61		1		66
UAC	31	35		7.6 (2.1–27.9)		81
BOC	48	14		12.8 (3.3–48.9)		91
Age (years)			0.012		0.37		0.78
≤30	58	39		1		87
>30	36	19		0.8 (0.4–1.4)		83
CA 125 (U/mL)			0.035		0.03		0.58
≤300	39	42		1		82
>300	39	15		2.1 (1.1–4.1)		84
Surgical approach			0.90				0.97
Laparotomy	55	29				84
Laparoscopy	39	21				89
Complete staging			0.27				0.54
Yes	41	32				84
No	53	22				88
FIGO stage			0.38				0.26
I	48	29				92
II–III	46	25				79
SBOT-MP			0.051		0.026		0.006
No	31	42		1		97
Yes	63	15		2.0 (1.1–3.7)		82
Implants			0.68				0.60
No	48	29				92
Noninvasive	36	28				75
Invasive	10	21				74
Chemotherapy			0.33				0.15
No	76	30				92
Yes	18	11				68

	N	Recurrence-free survival	Invasive recurrence-free survival
Total	94
Fertility sparing surgery			0.003		0.001		0.75
No	15	61		1		66
UAC	31	35		7.6 (2.1–27.9)		81
BOC	48	14		12.8 (3.3–48.9)		91
Age (years)			0.012		0.37		0.78
≤30	58	39		1		87
>30	36	19		0.8 (0.4–1.4)		83
CA 125 (U/mL)			0.035		0.03		0.58
≤300	39	42		1		82
>300	39	15		2.1 (1.1–4.1)		84
Surgical approach			0.90				0.97
Laparotomy	55	29				84
Laparoscopy	39	21				89
Complete staging			0.27				0.54
Yes	41	32				84
No	53	22				88
FIGO stage			0.38				0.26
I	48	29				92
II–III	46	25				79
SBOT-MP			0.051		0.026		0.006
No	31	42		1		97
Yes	63	15		2.0 (1.1–3.7)		82
Implants			0.68				0.60
No	48	29				92
Noninvasive	36	28				75
Invasive	10	21				74
Chemotherapy			0.33				0.15
No	76	30				92
Yes	18	11				68

Table II

Prognostic factors for recurrence (borderline and invasive) and invasive recurrence in women with bilateral serous borderline ovarian tumors (SBOT).

	N	Recurrence-free survival				Invasive recurrence-free survival
		Univariate analysis		Multivariate analysis		Univariate analysis
		5-year disease-free survival (%)	P	Hazard ratio (95% CI)	P	5-year invasive disease-free survival (%)	P
Total	94
Fertility sparing surgery			0.003		0.001		0.75
No	15	61		1		66
UAC	31	35		7.6 (2.1–27.9)		81
BOC	48	14		12.8 (3.3–48.9)		91
Age (years)			0.012		0.37		0.78
≤30	58	39		1		87
>30	36	19		0.8 (0.4–1.4)		83
CA 125 (U/mL)			0.035		0.03		0.58
≤300	39	42		1		82
>300	39	15		2.1 (1.1–4.1)		84
Surgical approach			0.90				0.97
Laparotomy	55	29				84
Laparoscopy	39	21				89
Complete staging			0.27				0.54
Yes	41	32				84
No	53	22				88
FIGO stage			0.38				0.26
I	48	29				92
II–III	46	25				79
SBOT-MP			0.051		0.026		0.006
No	31	42		1		97
Yes	63	15		2.0 (1.1–3.7)		82
Implants			0.68				0.60
No	48	29				92
Noninvasive	36	28				75
Invasive	10	21				74
Chemotherapy			0.33				0.15
No	76	30				92
Yes	18	11				68

	N	Recurrence-free survival				Invasive recurrence-free survival
		Univariate analysis		Multivariate analysis		Univariate analysis
		5-year disease-free survival (%)	P	Hazard ratio (95% CI)	P	5-year invasive disease-free survival (%)	P
Total	94
Fertility sparing surgery			0.003		0.001		0.75
No	15	61		1		66
UAC	31	35		7.6 (2.1–27.9)		81
BOC	48	14		12.8 (3.3–48.9)		91
Age (years)			0.012		0.37		0.78
≤30	58	39		1		87
>30	36	19		0.8 (0.4–1.4)		83
CA 125 (U/mL)			0.035		0.03		0.58
≤300	39	42		1		82
>300	39	15		2.1 (1.1–4.1)		84
Surgical approach			0.90				0.97
Laparotomy	55	29				84
Laparoscopy	39	21				89
Complete staging			0.27				0.54
Yes	41	32				84
No	53	22				88
FIGO stage			0.38				0.26
I	48	29				92
II–III	46	25				79
SBOT-MP			0.051		0.026		0.006
No	31	42		1		97
Yes	63	15		2.0 (1.1–3.7)		82
Implants			0.68				0.60
No	48	29				92
Noninvasive	36	28				75
Invasive	10	21				74
Chemotherapy			0.33				0.15
No	76	30				92
Yes	18	11				68

UAC, unilateral adnexectomy plus contralateral cystectomy; BOC, bilateral ovarian cystectomy; FIGO, International Federation of Gynecology and Obstetrics; SBOT-MP, SBOT with microcapillary pattern

This Feature Is Available To Subscribers Only